Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs

Scientia Pharmaceutica

Volumn 79, Issue 4, 2011, Pages 705-727

  Nanjwade, Basavaraj K ^a   Patel, Didhija J ^a   Udhani, Ritesh A ^a   Manvi, Fakirappa V ^a  

^a K L E S S COLLEGE OF PHARMACY   (India)

Author keywords

Isotropic lipid solutions; Lipid digestion; Lipids; Mean emulsion droplet diameter; Self emulsifying drug delivery system

Indexed keywords

(5ALPHA,17BETA) 2 CHLORO 3 [(4 NITROPHENOXY)IMINO]ANDROSTAN 17 YL ACETATE; AGENARASE; ALFACALCIDOL; ANDROSTANE DERIVATIVE; ANTIMALARIAL AGENT; BEXAROTENE; CALCITRIOL; CINNARIZINE; CIPROFLOXACIN; CLOFAZIMINE; CLOMETHIAZOLE; CYCLOSPORIN; CYCLOSPORIN A; DOXERCALCIFEROL; DRONABINOL; DRUG VEHICLE; EFAVIRENZ; EPADEL; EXCIPIENT; FENOGAL; IBUDILAST; INDOMETACIN FARNESIL; LIPID; LIPID EMULSION; LIPOSOME; MENATETRENONE; MORPHINE SULFATE; PENCLOMEDINE; PHENYTOIN; RITONAVIR; SOLID LIPID NANOPARTICLE; STEROID; SURFACTANT; TIPRANAVIR; TOLTERODINE; TRIACYLGLYCEROL; TRIAMTERENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; GASTROINTESTINAL TRACT; HUMAN; HYDROLYSIS; HYDROPHILICITY; HYDROPHOBICITY; INTESTINE; INTESTINE MUCOSA PERMEABILITY; INTESTINE TRANSIT TIME; LIPID SOLUBILITY; LIPOPHILICITY; MICROEMULSION; NANOENCAPSULATION; NONHUMAN; PARTITION COEFFICIENT; PH; PHYSICAL CHEMISTRY; REVIEW; SAPONIFICATION; SOLUBILIZATION; STOMACH MUCOSA; WETTABILITY;

EID: 82055180469     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1105-09     Document Type: Review

References (51)

1. Stuchlik M, Stanislav Z. Lipid based vehicle for oral drug delivery. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2001; 145: 17-26. http://www.ncbi.nlm.nih.gov/pubmed/12426768
2. Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007; 59: 667-676. http://dx.doi.org/10.1016/j.addr.2007.05.006
3. Schneider M. Investigation of the transport of lipophilic drugs in structurally diverse lipid formulations through caco-2 cell monolayer using mathematical modeling. PhD Thesis, University of Basel, Switzerland, 2008.
4. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water-soluble drugs. Adv Drug Deliv Rev. 1997; 25: 103-128. http://dx.doi.org/10.1016/S0169-409X(96)00494-2
5. Kossena GK, Charman WN, Boyd BJ, Dunstan DE, Porter CJH. Predicting drug solubilization patterns in the gastrointestinal tract after administration of lipid based delivery systems: A phase diagram approach. J Pharm Sci. 2004; 93: 332-348. http://dx.doi.org/10.1002/jps.10554
6. Shackleford DM, Porter CJH, Charman WN. Problems addressable by prodrugs. In: Stell VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley JW; Eds. Prodrugs: Challenges and Rewards. Springer, 2006: AAPS Press, 657. http://dx.doi.org/10.1007/978-0-387-49785-3_18
7. Dahan A, Hoffman A. Rationalizing and selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water-soluble drugs. J Control Release. 2007; 129: 1-10. http://dx.doi.org/10.1016/j.jconrel.2008.03.021
8. Charman WN, Porter CJH, Mithani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH. J Pharm Sci. 2000; 86: 269-282. http://dx.doi.org/10.1021/js960085v
9. Hoffman NE, Simmonds WJ, Morgan RG. The effect of mecellar solubilization on mucosal metabolism of absorbed glyceryl-l-monoether. Aust J Exp Biol Med Sci.1972; 50: 803-812. http://dx.doi.org/10.1038/icb.1972.77
10. Simmonds WJ. The role of micellar solubilization in lipid absorption. Aust J Exp Biol Med Sci.1972; 50: 403-421. http://dx.doi.org/10.1038/icb.1972.35
11. Westergaard H, Dietschy JM. The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into intestinal mucosal cell. J Clin Invest. 1976; 58: 97-108. http://dx.doi.org/10.1172/JCI108465
12. Shiau YF. Mechanism of intestinal fatty acid uptake in rat: the role of an acidic microclimate. J Physiol1990; 421: 463-474. http://www.ncbi.nlm.nih.gov/pubmed/2348399
13. Keleman RJ, Shaiu YF, Reed MA. Acidic mucin layer facilitates micelle dissociation and fatty acid diffusion. Am J Physiol. 1990; 259: G671-G675. http://www.ncbi.nlm.nih.gov/pubmed/2221076
14. Embleton JK, Pouton CW. Structure and function of gastrointestinal lipases. Adv Drug Deliv Rev.1997; 25: 15-32. http://dx.doi.org/10.1016/S0169-409X(96)00488-7
15. Shah NH, Carvajal MT, Patel CI. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm.1994; 106: 15-23. http://dx.doi.org/10.1016/0378-5173(94)90271-2
16. Charman SA, Charman WN, Rogge MC. Self-emulsifying drug delivery systems: Formulations and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm Res.1992; 9: 87-93. http://dx.doi.org/10.1023/A:1018987928936
17. Pouton CW. Self-emulsifying drug delivery systems: Assessment of the efficacy of emulsification. Int J Pharm. 1985; 27: 335-348. http://dx.doi.org/10.1016/0378-5173(85)90081-X
18. Kovarik JM, Meuller EA, Van Bree JB. Reduced inter and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci.1994; 83: 444-446. http://dx.doi.org/10.1002/jps.2600830336
19. Porter CJH, Charman WN. Uptake of drugs into intestinal lymphatics after oral administration. Adv Drug Deliv Rev.1997; 25: 71-90. http://dx.doi.org/10.1016/S0169-409X(96)00492-9
20. Porter CJH, Charman SA, Charman WN. Lymphatic transport of halofantrine in the triple cannulated anesthesized rat model: Effect of lipid vehicle dispersion. J Pharm Sci. 1996; 85: 351-356. http://dx.doi.org/10.1021/js950221g
21. Hauss DJ. Lipid-based systems for oral drug delivery: Enhancing the bioavailability of poorly water-soluble drugs. Am Pharm Rev. 2002; 5: 22-28.
22. Hauss DJ. Lipid-based systems for oral drug delivery: Enhancing the bioavailability of poorly water-soluble drugs. Am Pharm Rev. 2002; 5: 22-28.
23. Eccleston GM. Microemulsions. In: Swarbrick J, Boylan JC; eds. Encyclopedia of pharmaceutical technology. Vol 9, Marcel Dekker, New York, 1992: 375-421.
24. Attwood D. Microemulsions. In: Krueter J; ed. Colloidal Drug Delivery Systems. Marcel Dekker, New York, 1994: 31-71
25. Swenson ES, Curatolo WJ. Intestinal permeability enhancement for proteins, peptides and other polar drugs: Mechanisms and potential toxicity. Adv Drug Deliv Rev.1992; 8: 39-92. http://dx.doi.org/10.1016/0169-409X(92)90015-I
26. Osborne DW, Middleton CA, Rogers RL. Alcohol-free microemulsions. J Dispersion Sci Technol. 1988; 9: 415-423. http://dx.doi.org/10.1080/01932698808943999
27. Aungst BJ, Nguyen NH, Rogers NJ. Amphiphilic vehicles improve the oral bioavailability of a poorly soluble HIV protease inhibitor at high doses. Int J Pharm. 1997; 156: 79-88. http://dx.doi.org/10.1016/S0378-5173(97)00189-0
28. Szuts EZ, Harosi FI. Solubility of retinoids in water. Arch Biochem Biophys.1991; 87: 297-304. http://dx.doi.org/10.1016/0003-9861(91)90482-X
29. Charman WN, Stella VJ. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm. 1986; 34: 175-178. http://dx.doi.org/10.1016/0378-5173(86)90027-X
30. Dumanli I. Characterization of gelling phenomenon of a lipid-based formulation. Master Thesis, University of Rhode Island, 1998.
31. Chakrabarti S, Belpaire FM. Bioavailability of Phenytoin in lipid containing dosage forms in rats. J Pharm Pharmacol.1978; 30: 330-331. http://dx.doi.org/10.1111/j.2042-7158.1978.tb13247.x
32. Abrams LS, Weintraub HS, Patrick JE, McGuire JL. Comparative bioavailability of lipophilic steroid. J Pharm Sci. 1978; 6: 1287-1290. http://dx.doi.org/10.1002/jps.2600670925
33. Yamoka Y, Robert RD, Stella VJ. Low melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: A model for other high melting sparingly water soluble drugs. J Pharm Sci. 1983; 72: 400-405. http://dx.doi.org/10.1002/jps.2600720420
34. Stella V, Haslam J, Yata N, Okada H, Lindenbaum S, Higuchi T. Enhancement of bioavailability of a hydrophobic amine antimalarial by formulation with oleic acid in a soft gelatin capsule. J Pharm Sci. 1978; 67: 1375-1377. http://dx.doi.org/10.1002/jps.2600671011
35. Tokumura T, Tatsuishi K, Kayano M, Machida Y, Nagai T. Enhancement of oral bioavailability of cinnarizine in oleic acid in beagle dogs. J Pharm Sci. 1987; 76: 286-288. http://dx.doi.org/10.1002/jps.2600760404
36. Patton TF. Effect of various vehicles and vehicles volumes on oral absorption of triamterene in rats. J Pharm Sci.1981; 70: 1131-1134. http://dx.doi.org/10.1002/jps.2600701010
37. Myers RA. Systemic bioavailability of penclomedine from oil in water emulsion administer intraduodenally to rats. Int J Pharm. 1992; 78: 217-226. http://dx.doi.org/10.1016/0378-5173(92)90374-B
38. Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001; 47: 165-196. http://dx.doi.org/10.1016/S0169-409X(01)00105-3
39. Zeng XM, Martin GP, Marriott C. The controlled delivery of drugs to the lung. Int J Pharm. 1995; 124: 149-164. http://dx.doi.org/10.1016/0378-5173(95)00104-Q
40. Barratt GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technol Today. 2000; 3: 163-171. http://dx.doi.org/10.1016/S1461-5347(00)00255-8
41. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int J Pharm. 1997; 154: 123-140. http://dx.doi.org/10.1016/S0378-5173(97)00135-X
42. Manosroi A, Kongkaneramit L, Manosroi J. Stability and transdermal absorption of topical amphotericin B liposome formulations. Int J Pharm. 2004; 270: 279-286. http://dx.doi.org/10.1016/j.ijpharm.2003.10.031
43. Brannon PL. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm. 1995; 116: 1-9. http://dx.doi.org/10.1016/0378-5173(94)00324-X
44. Alleman E, Gurny R, Doelker E. Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur J Pharm Biopharm. 1993; 39: 173-191.
45. Reithmeier H, Herrmann J, Gopferich A. Development and characterization of lipid microparticles as a drug carrier for somatostatin. Int J Pharm. 2001; 218: 133-143. http://dx.doi.org/10.1016/S0378-5173(01)00620-2
46. Hu F, Yuan H, Zhang H. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm. 2002; 239: 121-128. http://dx.doi.org/10.1016/S0378-5173(02)00081-9
47. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery; drug incorporation and physicochemical characterization. J Microencapsul. 1999; 16: 205-213. http://dx.doi.org/10.1080/026520499289185
48. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004; 95: 627-638. http://dx.doi.org/10.1016/j.jconrel.2004.01.005
49. Zur MA, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery- Drug release and release mechanism. Eur J Pharm Biopharm. 1998; 45: 149-155. http://dx.doi.org/10.1016/S0939-6411(97)00150-1
50. Hou D, Xie C, Huang K. The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials. 2003; 24: 1781-1785. http://dx.doi.org/10.1016/S0142-9612(02)00578-1
51. Constantinides P. Lipid microemulsion for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res. 1995; 12: 1561-1572. http://dx.doi.org/10.1023/A:1016268311867